22219073
2012 Jan 4
Approximately 550 million people worldwide are chronically infected with hepatitis B (HBV) or hepatitis C (HCV) virus. The clinical course of HBV and HCV infection is variable and can lead to a chronic but mild hepatitis or to liver cirrhosis and hepatocellular carcinoma (HCC)1. Therefore, antiviral therapy should be considered in patients with chronic hepatitis to prevent progression of disease. Here, we review the current indications and guidelines for antiviral therapy in chronic HBV and HCV infection.

